Advertisement

One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis

  • Alessandro Inno
  • Sandro Barni
  • Antonio Ghidini
  • Alberto Zaniboni
  • Fausto Petrelli
Review
  • 14 Downloads

Abstract

Introduction

One year is the standard duration of adjuvant trastuzumab for human epidermal receptor-2 (HER2) positive (HER2+) breast cancer (BC). Indeed, a shorter duration of trastuzumab can reduce cardiotoxicity and the costs involved and could provide the same benefit as a one-year treatment. We evaluated the available evidence from randomised controlled trials (RCTs) by comparing 1 year versus a shorter duration of adjuvant trastuzumab for HER2+ BC.

Patients and methods

A systematic search of PubMed, EMBASE, The Cochrane Library and conference proceedings was carried out in order to identify the RCTs that investigated a standard versus a shorter duration of adjuvant trastuzumab in HER2+ BC patients. Using the fixed and random effects models, the pooled hazard ratios (HRs) and risk ratio (RR) with 95% confidence intervals (CI) were calculated for overall survival (OS), disease-free survival (DFS) and cardiac events.

Results

Five RCTs with a total of 11,381 patients were included. Overall, one year of adjuvant trastuzumab improved OS (HR 1.22, 95% CI 1.07–1.39; P = 0.003) and DFS (HR 1.19, 95% CI 1.08–1.3; P < 0.001) compared with a shorter duration (6 months and 9 weeks). In the subgroup analysis, there was a trend towards better DFS with the 1-year duration for patients with high-risk features, and also for concomitant administration of chemotherapy and trastuzumab. Cardiac events were significantly lower with a shorter duration (RR 0.4, 95% CI 0.32–0.49; P < 0.001).

Conclusions

One-year adjuvant trastuzumab is associated with better DFS and OS compared with shorter durations and should still be considered the standard duration. However, selected patients with low-risk HER2+ BC can most likely be spared from an excess of cardiac toxicity with a shorter course.

Keywords

Breast cancer Adjuvant Trastuzumab Duration One year 

Notes

Funding

None received.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Research involving human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2lneu Oncogene. Science.  https://doi.org/10.1126/science.3798106 CrossRefPubMedGoogle Scholar
  2. 2.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672.  https://doi.org/10.1056/NEJMoa052306 CrossRefPubMedGoogle Scholar
  3. 3.
    Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684.  https://doi.org/10.1056/NEJMoa052122 CrossRefPubMedGoogle Scholar
  4. 4.
    Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273–1283.  https://doi.org/10.1056/NEJMoa0910383 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Perez EA, Romond EH (2014) Suman V. J. et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32(33):3744–3752.  https://doi.org/10.1200/JCO.2014.55.5730 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Smith I, Procter M, Gelber RD et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet.  https://doi.org/10.1016/S0140-6736(07)60028-2 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Gianni L, Dafni U, Gelber RD et al (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol.  https://doi.org/10.1016/S1470-2045(11)70033-X CrossRefPubMedGoogle Scholar
  8. 8.
    Cameron D, Piccart-Gebhart MJ, Gelber RD et al (2017) 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the Herceptin adjuvant (HERA) trial. Lancet.  https://doi.org/10.1016/S0140-6736(16)32616-2 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Goldhirsch A, Gelber RD, Piccart-Gebhart MJ et al (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897):1021–1028.  https://doi.org/10.1016/S0140-6736(13)61094-6 CrossRefPubMedGoogle Scholar
  10. 10.
    Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al (2006) Adjuvant cocetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809–820.  https://doi.org/10.1056/NEJMoa053028 CrossRefPubMedGoogle Scholar
  11. 11.
    Joensuu H, Bono P, Kataja V et al (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol 27(34):5685–5692.  https://doi.org/10.1200/JCO.2008.21.4577 CrossRefPubMedGoogle Scholar
  12. 12.
    Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339(1):b2535–b2535.  https://doi.org/10.1136/bmj.b2535 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12.  https://doi.org/10.1016/0197-2456(95)00134-4 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Wells GA, Shea B, O’Connell D et al (2014) The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. Ottawa Hosp Res Inst. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 13 Aug 2014
  15. 15.
    Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ Br Med J 327(7414):557–560.  https://doi.org/10.1136/bmj.327.7414.557 CrossRefGoogle Scholar
  16. 16.
    C P (2017) P. C, G. B et al. Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1-year adjuvant trastuzumab for HER21 early breast cancer. Ann Oncol.  https://doi.org/10.1093/annonc/mdx421 CrossRefGoogle Scholar
  17. 17.
    Joensuu H, Fraser J, Wildiers H et al (2018) Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial. JAMA Oncol.  https://doi.org/10.1001/jamaoncol.2018.1380 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I (2015) Six versus twelve months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol 26(7):1333–1340PubMedGoogle Scholar
  19. 19.
    Pivot X, Romieu G, Debled M et al (2013) 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 14(8):741–748.  https://doi.org/10.1016/S1470-2045(13)70225-0 CrossRefPubMedGoogle Scholar
  20. 20.
    Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S (2008) Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 13(6):620–630.  https://doi.org/10.1634/theoncologist.2008-0001 CrossRefPubMedGoogle Scholar
  21. 21.
    Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(6): e1000097.  https://doi.org/10.1371/journal.pmed1000097. http://www.prisma-statement.org
  22. 22.
    Denduluri N, Chavez-MacGregor M, Telli ML et al. Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2018:JCO2018788604.  https://doi.org/10.1200/JCO.2018.78.8604 CrossRefGoogle Scholar
  23. 23.
    Gyawali B, Niraula S (2017) Duration of adjuvant trastuzumab in HER2 positive breast cancer: overall and disease-free survival results from meta-analyses of randomized controlled trials. Cancer Treat Rev 60:18–23.  https://doi.org/10.1016/j.ctrv.2017.08.001 CrossRefPubMedGoogle Scholar
  24. 24.
    Murray GD (2001) Switching between superiority and non-inferiority. Br J Clin Pharmacol 52(3):219.  https://doi.org/10.1046/j.0306-5251.2001.01397.x CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    von Minckwitz G, Procter M, de Azambuja E et al (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377(2):122–131.  https://doi.org/10.1056/NEJMoa1703643 CrossRefGoogle Scholar
  26. 26.
    Martin M, Holmes FA, Ejlertsen B et al (2017) Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase-3 trial. Lancet Oncol 18(12):1688–1700.  https://doi.org/10.1016/S1470-2045(17)30717-9 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Oncology Unit, Cancer Care CenterIRCCS Ospedale Sacro Cuore Don CalabriaNegrar, VeronaItaly
  2. 2.Oncology Unit, Medical Sciences DepartmentASST Bergamo OvestTreviglioItaly
  3. 3.Oncology UnitCasa di Cura IgeaMilanItaly
  4. 4.Oncology UnitCasa di Cura PoliambulanzaBresciaItaly

Personalised recommendations